Management Team

BURT D. ENSLEY has been a Director of the Company since its inception in 1993. From 2000 to 2004, Dr. Ensley has served as the VP of Research and President of NuCycle Therapy, a subsidiary of Integrated BioPharma, (INB). From 1993 through 2000, Dr. Ensley was President, Chief Executive Officer and Director of Phytotech, Inc. A phytoremediation company. Phytotech was sold in 2000. From 1989 through 1992, Dr. Ensley served as Director of Advanced Technology at Envirogen, Inc., a microbial based bioremediation company. From 1981 to 1989, Dr. Ensley headed the Specialty Chemicals Group at Amgen, Inc. Dr. Ensley received a B.S. and M.S. in Biology from the University of New Mexico and a Ph.D. in Microbiology from the University of Georgia in 1979. Since 1996, Dr. Ensley served on the National Science Foundation’s BIO Directorate Advisory Board and as a Fellow of the American Academy of Microbiology.

LORENZO A. DELUCA has served as a Director since April 2004. Mr. DeLuca is the owner and President of Paxton Ventures Corp., a venture capital and consulting firm specializing in emerging growth companies. In connection with Paxton’s portfolio investments, Mr. DeLuca has served as officer or director of Action Industries Inc., General Vision Services, Inc., Bio-Reference Laboratories and Merchants Advantage.com. Mr. DeLuca is an attorney admitted to practice in the State of New York and was a founding member of Zervas & DeLuca. Mr. DeLuca received a BA degree from Rutgers College and a J.D. degree from New York Law School.

ROBERT S. KELLAR, Advisory Board Member, brings extensive experience in research and product development for FDA regulated products. Dr. Kellar is the former VP of Research and Development for Histogen, Inc., a regenerative medicine company in San Diego, CA. He has served as a lead scientist in discussions with the FDA on the challenges of new biologic product regulations and has brought a number of regulated products to market. Within the medical device industry, Dr. Kellar has served in a variety of roles, including management oversight for research & development, clinical studies, manufacturing, regulatory approval, marketing and sales of medical devices. Dr. Kellar is the Founder and President of Development Engineering Sciences, a firm based in Flagstaff, Arizona. Kellar's previous experience in the biomedical industry also includes prior positions with W.L. Gore & Associates and Advanced Tissue Sciences. Dr. Kellar serves on the Scientific Advisory Board for Theregen, a cell therapy company investigating the cardiovascular applications of the cell-based human tissue patch, Angerina™. Dr. Kellar also holds an Adjunct Professor Faculty position in Mechanical Engineering at Northern Arizona University.

WARREN A. CARSEY has been with the Company as an investor and manager of finance and business development since early 2008. In 1999 Mr. Carsey founded Veritas Holdings, an investment and financial advisory firm specializing in financing intellectual property and new technologies. From 2004 through 2007, Mr. Carsey co-founded managed QD Products, a developer of advanced polymers for the defense industry, selling his interests in 2007. Prior to founding Veritas, Warren worked as a banker at CIBC World Markets in New York specializing in structured finance. Before CIBC, he was a banker at Chase Securities (now JPMorgan Chase) in New York. Mr. Carsey received a B.S. degree from Northern Arizona University in 1989 and an MBA from the University of Michigan in 1995.